PSA blood test: what high PSA levels mean, normal range by age and free PSA
Prostate-specific antigen (PSA) (PSA) · PSA (ordered alone, or with free PSA) · reported in ng/mL (equivalent to mcg/L)
Prostate-specific antigen (PSA) is a protein made by the prostate gland that liquefies semen, and a small amount leaks into the blood. A PSA blood test measures that amount in nanograms per millilitre. The traditional cut-off is 4.0 ng/mL, but PSA rises naturally with age and prostate size, so age-specific upper limits are often used: about 2.5 ng/mL in your 40s, 3.5 in your 50s, 4.5 in your 60s and 6.5 in your 70s. The median PSA for a man in his 40s is around 0.7 ng/mL.
The two most common reasons for a raised PSA are not cancer. Benign prostatic enlargement (BPH), which affects half of men over 60, slowly pushes PSA up as the gland grows, and prostatitis or a urinary infection can send it to 10, 20 or higher within days and take six to eight weeks to settle. Prostate cancer is the third common cause, and the reason the test exists: among men with a PSA between 4 and 10 ng/mL, about one in four has cancer on biopsy; above 10, more than half do. But cancer also occurs below 4, so no PSA value rules it out.
Because one number is so ambiguous, a raised PSA is now rarely followed straight by a biopsy. It is repeated after a few weeks, interpreted against your age, prostate size (PSA density), the proportion that is free rather than protein-bound (free PSA), how fast it is changing (PSA velocity), and increasingly a multiparametric MRI of the prostate. Whether to be screened at all is a personal decision: the US Preventive Services Task Force recommends that men aged 55 to 69 decide with their clinician, and advises against routine screening after 70.
PSA at a glance
- What it is: a protein made almost only by the prostate; a blood level reflects prostate size, inflammation, injury and cancer together.
- Normal: below 4.0 ng/mL is the traditional cut-off; age-specific limits are roughly 2.5 (40–49), 3.5 (50–59), 4.5 (60–69) and 6.5 ng/mL (70–79). A PSA under 1.0 at age 60 means a very low lifetime risk of dying from prostate cancer.
- High: 4–10 ng/mL is the 'grey zone' with about a 25 percent chance of cancer; above 10 the chance is over 50 percent. Infection, BPH, ejaculation, cycling, a recent catheter or biopsy also raise it.
- Free PSA helps in the 4–10 zone: a free-to-total ratio below 10 percent means a high chance of cancer (about 50 percent); above 25 percent means low (under 10 percent).
- Low PSA is not a problem; it is lowered by finasteride and dutasteride (roughly halved), obesity, and after prostate surgery, when it should be undetectable.
- Next step: repeat in 6 to 8 weeks (after treating any infection, no ejaculation for 48 hours), then free PSA, PSA density and usually an MRI before any biopsy.
Have your whole report? Paste it into the free Lab Explainer
Every marker explained in plain language, in context with the others, with questions to bring to your appointment. No account needed.
What PSA measures
PSA is a serine protease (kallikrein-3) secreted by the epithelial cells lining the prostate ducts into semen, where it breaks down the gel that forms after ejaculation. Normally only a tiny fraction crosses into the blood. Anything that disrupts the architecture of the gland lets more through: growth of the gland with age (BPH), inflammation, infection, instrumentation, and cancer, which disorganises the tissue so that PSA leaks at roughly 10 times the rate per gram of benign tissue. PSA is therefore prostate-specific but not cancer-specific.
In the blood, 70 to 90 percent of PSA is bound to proteins (mainly alpha-1-antichymotrypsin) and the rest circulates free. Cancer cells release proportionally more bound PSA, so the percentage of free PSA falls as the chance of cancer rises; the free PSA test is useful mainly when the total is 4 to 10 ng/mL. Labs use immunoassays that are now reasonably standardised to the WHO reference material, but values can still differ by 10 to 20 percent between methods, which is why a change should be confirmed on the same assay before it is acted on.
Derived measures add context. PSA density divides the PSA by the prostate volume measured on ultrasound or MRI; a density above 0.15 ng/mL per cc is more suspicious than the same PSA in a large benign gland. PSA velocity is the rate of change, historically flagged above 0.75 ng/mL per year (or 0.35 ng/mL per year at low levels), though guidelines no longer recommend biopsy on velocity alone because normal fluctuation is about 15 to 20 percent. PSA doubling time is used after treatment to gauge how fast a recurrence is growing.
Normal range for PSA
Reference ranges vary between labs and by age, sex and pregnancy. Use the range printed on your own report.
| Group | Typical range (ng/mL (equivalent to mcg/L)) | Notes |
|---|---|---|
| Traditional cut-off, all ages | Below 4.0 ng/mL | Used in most screening trials. About 15 percent of men with a PSA under 4 still have cancer on biopsy, most of it low grade. Labs differ slightly. |
| Age-specific upper limits (Oesterling 1993) | 40–49: 2.5; 50–59: 3.5; 60–69: 4.5; 70–79: 6.5 ng/mL | Reflect normal prostate growth with age; Black men and men of Asian ancestry have slightly different distributions. |
| Median PSA by age | 40s: about 0.7; 50s: about 0.9; 60s: about 1.2–1.4 ng/mL | A baseline above the median for age roughly doubles to quadruples later risk; a PSA under 1.0 at 60 carries a 0.2 percent risk of dying from prostate cancer by 85 (Vickers 2010). |
| Grey zone | 4.0–10.0 ng/mL | About 25 percent chance of cancer on biopsy; free PSA, PSA density and MRI refine the decision. Prostatitis and BPH commonly produce values here. |
| Raised | Above 10 ng/mL | Over 50 percent chance of cancer; a repeat after 6 to 8 weeks is still reasonable if infection is possible, since prostatitis can give 20 to 50 ng/mL or more. |
| Free PSA ratio (total 4–10) | Below 10 percent: about 50–56 percent cancer risk; 10–25 percent: intermediate; above 25 percent: about 8 percent risk | Catalona 1998. A 25 percent cut-off detects 95 percent of cancers while avoiding 20 percent of unnecessary biopsies. |
| PSA density | Below 0.10–0.15 ng/mL per cc is reassuring; above 0.15 is suspicious | Needs prostate volume from ultrasound or MRI. |
| On finasteride or dutasteride (5-alpha reductase inhibitors) | Roughly half the untreated value after 6–12 months | Double the measured PSA to compare with standard ranges; a rise from the nadir while on the drug is significant. |
| After radical prostatectomy | Undetectable (below 0.1 ng/mL) | A confirmed PSA of 0.2 ng/mL or more defines biochemical recurrence. After radiotherapy, recurrence is a rise of 2 ng/mL above the lowest value reached. |
High PSA
A PSA above the limit for your age means the prostate is leaking more PSA than usual, and the job is to work out why. In a man with urinary symptoms and a large gland on examination, BPH is the likeliest explanation, and PSA roughly tracks gland size (about 0.1 ng/mL per gram of benign tissue, so a 60 g prostate alone can produce a PSA of 4 to 6). In a man with pain, fever, burning on urination or a recent urinary infection, prostatitis is the likeliest explanation and can produce values of 10 to 50 ng/mL that fall back over six to eight weeks. In a man with neither, the question of cancer becomes more pressing.
The level and its context grade the concern. A PSA of 4 to 10 carries about a 25 percent chance of cancer, and of the cancers found about three-quarters are low or intermediate grade. Above 10 the chance exceeds 50 percent and the cancers are more often higher grade. A free PSA under 10 percent, a density above 0.15 ng/mL per cc, a rise of more than 0.75 ng/mL in a year confirmed on repeat, a firm nodule on rectal examination, a family history or BRCA mutation, and Black ancestry each increase the probability, and a multiparametric MRI showing a PI-RADS 4 or 5 lesion increases it considerably; a normal MRI (PI-RADS 1 or 2) lowers it enough that many men can avoid biopsy.
One raised value should not lead directly to a biopsy. Guidelines recommend repeating the PSA after a few weeks (after treating any infection and avoiding ejaculation and cycling for 48 hours), since about a quarter of raised values are normal on repeat. If it is still raised, the usual sequence is free PSA or another reflex marker, an MRI, and then a targeted biopsy if the MRI is suspicious. Transient rises after a catheter, cystoscopy, biopsy or acute urinary retention are expected and the test should wait six weeks.
Common causes
Benign prostatic hyperplasia (BPH)
The most common cause. The gland grows with age in most men and PSA rises about 0.1 ng/mL per gram of extra tissue, so a large benign prostate of 60 to 80 g can produce a PSA of 4 to 8. PSA density corrects for this.
Prostatitis and urinary tract infection
Acute bacterial prostatitis can push PSA to 20 to 50 ng/mL or more within days; chronic prostatitis and even asymptomatic inflammation found on biopsy raise it more modestly. Levels take 6 to 8 weeks to fall after treatment, so the test is repeated then.
Prostate cancer
Cancer disrupts the gland and releases roughly 10 times more PSA per gram than benign tissue; the risk is about 15 percent below 4 ng/mL, 25 percent at 4 to 10 and over 50 percent above 10. Some aggressive cancers make little PSA, so a normal value does not exclude it.
Ejaculation within 48 hours
Raises PSA by a small amount (up to about 0.4 to 0.8 ng/mL) for 24 to 48 hours in some men, enough to tip a borderline result over the line. Abstain for two days before the test.
Prostate manipulation: catheter, cystoscopy, biopsy, acute retention
A urinary catheter, a cystoscopy, a prostate biopsy or an episode of acute retention can raise PSA severalfold; wait at least 6 weeks after any of these. A digital rectal examination causes only a trivial rise and need not delay the test.
Vigorous cycling and perineal trauma
Long rides compress the perineum and prostate; studies are mixed, with small rises in some men. Avoid a long ride in the 48 hours before the test if a result will be borderline.
Age
PSA rises about 3 percent a year in healthy men, both from gland growth and from more leakage; this is why age-specific limits exist.
Testosterone treatment
Restoring testosterone in a hypogonadal man typically raises PSA by 0.3 to 0.5 ng/mL in the first year as the gland regains normal size; a rise of more than 1.4 ng/mL in a year or above 4.0 prompts urological review.
Stopping finasteride or dutasteride
These drugs roughly halve PSA; when they are stopped the level returns to its untreated value over several months, which can look like a sudden rise.
Prostate infarction, stones and rare non-prostate sources
Infarcts in a large gland and prostatic calculi cause transient rises. Tiny amounts of PSA come from periurethral glands and some breast and salivary tumours, but never enough to explain a clearly raised value in a man with a prostate.
Symptoms that can go with it
- Usually none; most raised PSAs are found on screening in men who feel well
- A weak or interrupted stream, hesitancy, straining, dribbling and incomplete emptying (BPH or any obstructing process)
- Getting up at night to urinate, frequency and urgency
- Burning on urination, fever, chills, pelvic or perineal pain and painful ejaculation with prostatitis
- Blood in the urine or semen, which always needs assessment
- Erectile dysfunction, which is common with BPH and prostatitis and occasionally with locally advanced cancer
- Bone pain (back, hips, ribs), weight loss, fatigue or leg swelling, which can indicate advanced prostate cancer and need prompt review
Low PSA
There is no lower limit of concern for PSA in a man who still has his prostate. A low or undetectable value means the gland is small, quiet and not inflamed, and in screening terms a low baseline is strongly reassuring: a PSA below 1.0 ng/mL at age 60 is associated with a 0.2 percent risk of dying from prostate cancer by 85, low enough that many guidelines allow screening to stop or the interval to stretch to several years. A PSA below 1.0 at age 45 to 50 similarly allows a longer interval between tests.
Some low values need interpreting. Finasteride and dutasteride, taken for BPH or hair loss, halve PSA within 6 to 12 months, so the measured value should be doubled to compare with the usual ranges; a rise from the lowest value on the drug is significant even if the absolute number is small. Obesity lowers PSA by 10 to 20 percent through dilution in a larger blood volume, which can mask a cancer slightly. Androgen deprivation therapy, low testosterone and anything that shrinks the gland lower PSA. After a radical prostatectomy PSA should be undetectable (below 0.1 ng/mL), and a confirmed rise to 0.2 or more is the definition of recurrence, so 'low' here is the goal, not a problem.
Common causes
A small, healthy prostate
Young men and men with small glands have PSA of 0.3 to 1.0 ng/mL; this is the expected result and carries a very low long-term cancer risk.
Finasteride or dutasteride
5-alpha reductase inhibitors shrink the gland and halve PSA by 6 to 12 months (and by about two-thirds after several years); double the result to interpret it and watch for any rise from the nadir.
Obesity
Larger plasma volume dilutes PSA by roughly 10 to 20 percent in men with a BMI over 35, and lower testosterone in obesity shrinks the gland; some clinicians adjust the threshold down slightly.
Androgen deprivation therapy or low testosterone
PSA production is androgen-dependent; castration-level testosterone drives PSA toward zero even when cancer is present, which is why PSA is tracked together with testosterone during treatment.
After radical prostatectomy
With the gland removed PSA should fall to undetectable within about 6 weeks; any confirmed value of 0.2 ng/mL or more indicates residual or recurrent cancer.
Some medications
Statins, thiazide diuretics, NSAIDs and acetaminophen are associated with slightly lower PSA (a few percent) in observational studies; the effect is too small to matter clinically but adds to the noise.
Symptoms that can go with it
- None; a low PSA does not cause symptoms
- Urinary symptoms with a low PSA still need assessment, since bladder, urethral and neurological causes do not raise PSA, and neither does a poorly differentiated cancer
Read it alongside
- Free PSA (and the free-to-total ratio) — the first add-on when total PSA is 4 to 10 ng/mL; a ratio under 10 percent roughly doubles the probability of cancer and over 25 percent reassures.
- Prostate volume (ultrasound or MRI) and PSA density — separates a large benign gland from a small gland that is leaking too much PSA; density above 0.15 ng/mL per cc is suspicious.
- Previous PSA values — the trend (velocity and doubling time) matters more than one value; a confirmed rise of more than 0.75 ng/mL a year is a flag, but year-to-year noise of 15 to 20 percent is normal.
- Urinalysis and urine culture — a positive leukocyte esterase or nitrite points to infection as the cause and means the PSA should be repeated after treatment.
- Multiparametric prostate MRI (PI-RADS score) — now recommended before a first biopsy; a PI-RADS 1 or 2 result lowers the chance of significant cancer enough to defer biopsy in most men.
- Testosterone — low testosterone and androgen deprivation lower PSA; testosterone replacement raises it; both change how a value should be read.
- Reflex biomarkers (PHI, 4Kscore, PCA3, SelectMDx) — blood or urine tests used in the grey zone to estimate the chance of high-grade cancer before biopsy.
- Alkaline phosphatase and calcium — raised with bone involvement in advanced prostate cancer; checked when PSA is very high (over 20 to 50) or there is bone pain.
What usually happens next
- A first raised PSA is repeated after 6 to 8 weeks on the same assay, after any urinary infection has been treated and with no ejaculation, cycling or prostate procedures in the preceding 48 hours to 6 weeks; about a quarter return to normal.
- If still raised, expect a rectal examination, a free PSA or another reflex marker, and in most centres a multiparametric MRI of the prostate, which guides whether a biopsy is needed and where to target it.
- A biopsy, if done, is usually MRI-targeted plus systematic cores, often through the perineum rather than the rectum to reduce infection; the result is graded by Gleason score or Grade Group 1 to 5.
- Ask what your PSA density is, how your value compares with the median for your age, and whether your free PSA percentage changes the picture; these three often decide between watching and biopsy.
- If you are 55 to 69 and considering screening, or 70 or older and still being screened, ask about the trade-off: in the European screening trial about 780 men had to be screened and 27 diagnosed to prevent one prostate cancer death over 13 years, while overdiagnosis and biopsy complications are the main harms.
- Men with a PSA under 1.0 at 60, or under 1.0 at 45 to 50, can reasonably lengthen the interval to 2 to 4 years or more; men with a family history, BRCA2 mutation or Black ancestry are generally advised to start earlier (40 to 45) and test more often.
Diet, lifestyle and natural levers with evidence
What can move PSA once the cause is known. Nothing here replaces finding the cause.
Allow time and treat infection before retesting
Strong evidenceThe most reliable way to lower a falsely raised PSA is to remove the cause and wait. In studies of men with a first PSA over 4, around 25 percent were under 4 on repeat a few weeks later with no treatment, and PSA raised by prostatitis takes 6 to 8 weeks to return to baseline after antibiotics. Two days without ejaculation or long cycling before the sample avoids the small rises these cause.
Mediterranean or plant-forward diet and limiting processed meat and dairy
Moderate evidenceLarge cohorts (Health Professionals Follow-up Study, CaPSURE, the MEAL trial of men on active surveillance) link higher vegetable, legume, fish and olive-oil intake and lower intake of processed meat, high-fat dairy and sugar-sweetened drinks with less progression and lower prostate cancer mortality, with risk reductions of around 20 to 30 percent between highest and lowest adherence. Dietary pattern has little direct effect on the PSA number itself over months; its evidence is about outcomes, not the test.
Regular exercise and weight control
Moderate evidenceMen who do 3 or more hours a week of vigorous activity after a prostate cancer diagnosis had about 60 percent lower prostate cancer mortality in the Health Professionals cohort, and obesity is associated with more aggressive disease and worse outcomes. Exercise does not lower PSA directly (and obesity actually lowers the measured value by dilution), so these are levers for prostate health rather than for the number.
Tomatoes and lycopene
Preliminary evidenceMen eating 2 or more servings of tomato sauce a week had about 20 percent lower prostate cancer risk in cohort studies, but randomised trials of lycopene supplements (15 to 30 mg a day for 3 to 12 months) in men with raised PSA or on active surveillance show small and inconsistent changes in PSA, and a 2013 meta-analysis found no significant effect. Eating tomatoes is reasonable; supplements have not been shown to lower PSA.
Green tea catechins
Preliminary evidenceIn a 1-year trial of 60 men with high-grade PIN (a precancerous finding), 600 mg a day of green tea catechins was followed by cancer in 1 of 30 men versus 9 of 30 on placebo; a larger 2015 trial of 97 men found no significant difference in cancer diagnoses but a small fall in PSA (about 0.9 ng/mL) in the catechin group. Evidence is promising but limited to small trials.
Concentrated green tea extracts have caused liver injury in some users, particularly on an empty stomach; stay under about 800 mg of EGCG a day and stop if nausea or dark urine develop.
Pomegranate juice or extract
Preliminary evidenceAn uncontrolled 2006 study in men with rising PSA after treatment reported the PSA doubling time lengthening from 15 to 54 months on 8 oz of pomegranate juice a day, but the subsequent placebo-controlled trial of 183 men found no difference in doubling time between extract and placebo. It is safe to drink but should not be relied on to change PSA.
When to see a clinician promptly
- A PSA above 10 ng/mL, or a confirmed rise of more than 0.75 ng/mL in a year, needs urological assessment within weeks; a PSA above 20 to 50 with bone pain or weight loss needs urgent referral.
- Fever, chills, severe pelvic or perineal pain and difficulty passing urine with a high PSA: acute bacterial prostatitis, which needs same-day treatment and can progress to sepsis.
- Inability to pass urine at all (acute retention), with a full painful bladder: an emergency needing catheterisation.
- Blood in the urine or semen, new bone pain, unexplained weight loss, or weakness or numbness in the legs (possible spinal cord compression from metastases: an emergency).
- Any PSA above the age-specific limit (2.5 in your 40s, 3.5 in your 50s, 4.5 in your 60s), to arrange a repeat and discuss free PSA and MRI.
- After prostate cancer treatment, any confirmed PSA of 0.2 ng/mL or more after prostatectomy, or a rise of 2 above the nadir after radiotherapy.
Frequently asked questions
What is a normal PSA level by age?
The commonly used age-specific upper limits are 2.5 ng/mL for men in their 40s, 3.5 in their 50s, 4.5 in their 60s and 6.5 in their 70s, with 4.0 as the traditional single cut-off. Median values are much lower: about 0.7 ng/mL in the 40s, 0.9 in the 50s and 1.2 to 1.4 in the 60s. Being above the median for your age raises later risk, and being below 1.0 at age 60 means a very low lifetime risk, so where you sit within 'normal' carries information too.
Is a PSA of 4 high?
It is at the traditional threshold and above the age-specific limit for men under 60. A PSA of 4 to 10 carries roughly a one in four chance of cancer on biopsy, which means a three in four chance it is BPH, inflammation or normal variation. The next steps are a repeat in 6 to 8 weeks, a free PSA (a ratio over 25 percent is reassuring, under 10 percent concerning), a PSA density if your prostate volume is known, and usually an MRI before any biopsy.
Is a PSA of 6 high?
Yes for a man under 70 and borderline for a man in his 70s, where the age-specific limit is 6.5. In the 4 to 10 range the chance of cancer is about 25 percent and rises toward the upper end, but a 70 g benign prostate can produce a PSA of 6 to 7 on its own, and prostatitis can produce far more. Free PSA, PSA density and an MRI usually settle whether a biopsy is needed.
What is the free PSA ratio and what is a good number?
Free PSA is the fraction not bound to proteins, expressed as a percentage of total PSA. Cancer releases proportionally more bound PSA, so a low free percentage is more worrying. When total PSA is 4 to 10 ng/mL, a free PSA above 25 percent carries about an 8 percent chance of cancer and below 10 percent about a 50 percent chance; 10 to 25 percent is intermediate. It is not useful when total PSA is under 4 or over 10, and finasteride and prostatitis change the ratio.
What raises PSA besides cancer?
Benign prostate enlargement (the most common cause), prostatitis or a urinary infection (which can raise PSA to 20 to 50 or more), ejaculation in the previous 48 hours, a urinary catheter, cystoscopy or biopsy in the previous 6 weeks, acute urinary retention, long cycling rides, testosterone treatment and simply getting older. A rectal examination causes only a trivial rise. Stopping finasteride or dutasteride makes PSA climb back to its untreated level, which can look like a rise.
Should I have a PSA test?
The US Preventive Services Task Force (2018) says men aged 55 to 69 should decide individually with their clinician after discussing benefits and harms, and recommends against screening at 70 or older. The American Urological Association (2023) supports shared decision-making from 45 to 50 up to 69, starting at 40 to 45 for men at higher risk (Black men, a father or brother with prostate cancer, BRCA mutations), with testing every 2 to 4 years. The benefit is roughly one prostate cancer death prevented per 570 men screened over 16 years; the harms are false alarms, biopsy complications and treating cancers that would never have caused trouble.
How fast can PSA rise, and what is PSA velocity?
PSA velocity is the change per year. Historically a rise of more than 0.75 ng/mL per year (or 0.35 per year when PSA is under 4) was a trigger for biopsy, but normal fluctuation is 15 to 20 percent and infection can add 10 or 20 points in a week, so current guidelines do not recommend biopsy on velocity alone. A sustained rise confirmed on repeat testing, especially when the free PSA is low or the MRI is abnormal, is meaningful. After treatment, PSA doubling time (how long it takes to double) is the key measure: under 10 to 12 months indicates a faster-growing recurrence.
Does finasteride or dutasteride affect my PSA?
Yes. Both roughly halve PSA within 6 to 12 months, and after several years the reduction is closer to two-thirds. To compare with the usual ranges, double your measured value (or multiply by 2.3 after 7 or more years). Any rise from your lowest value while on the drug is significant, even if the absolute number is still 'normal'. Make sure whoever orders the test knows you take one, including for hair loss.
References
- Prostate-specific antigen (PSA) test. MedlinePlus, US National Library of Medicine (2023)View source
- Prostate-specific antigen (PSA) test fact sheet. National Cancer Institute (2022)View source
- Grossman DC, Curry SJ, Owens DK, et al.. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA (2018)View source
- Wei JT, Barocas D, Carlsson S, et al.. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. Journal of Urology (2023)
- Catalona WJ, Partin AW, Slawin KM, et al.. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA (1998)
- Thompson IM, Pauler DK, Goodman PJ, et al.. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. New England Journal of Medicine (2004)View source
- Oesterling JE, Jacobsen SJ, Chute CG, et al.. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA (1993)
- Vickers AJ, Cronin AM, Björk T, et al.. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010)
- Schröder FH, Hugosson J, Roobol MJ, et al.. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet (2014)
- Pantuck AJ, Pettaway CA, Dreicer R, et al.. A randomized, double-blind, placebo-controlled trial of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer and Prostatic Diseases (2015)
- Kumar NB, Pow-Sang J, Egan KM, et al.. Randomized, placebo-controlled trial of green tea catechins for prostate cancer prevention. Cancer Prevention Research (2015)
- Prostate cancer. Merck Manual Professional Version (2024)
Related markers
Related conditions
Evidence guides
Worried about your number?
Ask AskMN what your PSA result could mean in the context of your other results, symptoms and medications. Free, unlimited, no account needed.
Ask about my PSAThis page is educational and is not medical advice or a diagnosis. Lab results have to be interpreted together with your history, symptoms and other results by a clinician who knows you. Do not start or stop a supplement to change a lab value before the cause is known.